The Early Onset of Disease May Be a Risk Factor for Decreased Bone Mineral Density in Patients with Inflammatory Bowel Disease

Overview

Journal Clin Endosc

Date 2013 Feb 21

PMID 23423611

Citations 5

Authors

Hwa Jong Kim

Su Jin Hong

Young Woo Jeon

Jae Pil Han

Seung Hyo Han

Jee Heon Kang

Jae Woong Tae

Hee Sook Lim

Hee Kyung Kim

Bong Min Ko

Moon Sung Lee

Affiliations

Soon will be listed here.

Abstract

Background/aims: The pathogenesis of bone loss in patients with inflammatory bowel disease (IBD) is complex, multifactorial, and only partly understood. We aimed to examine the extent and risk factors of bone mass reduction and to analyze the impact of early onset of a disease before attaining peak bone mass in IBD patients.

Methods: We compared the risk factors for osteoporosis and BMD at the lumbar spine and the hip bone in IBD patients.

Results: A total of 44 patients with IBD were enrolled. Twenty-one and 23 patients were diagnosed as IBD before and after the age of 30 and designated as group A and group B, respectively. Group A had significant bone mass reduction at the lumbar spine than group B (BMD, 1.01±0.10 vs. 1.14±0.17, p<0.01; T-score, -1.22±0.84 vs. -0.08±1.39, p<0.01; Z-score, -1.11±0.81 vs. -0.03±1.32, p<0.01, respectively). Multivariate analysis showed that patients diagnosed as IBD before the age of 30 had possible risk factor of bone mass reduction (hazard ratio, 3.96; p=0.06).

Conclusions: Bone mass reduction was more severe in patients who were diagnosed with IBD before the age of 30 than in those diagnosed after the age of 30.

Citing Articles

Small and Large Intestine (II): Inflammatory Bowel Disease, Short Bowel Syndrome, and Malignant Tumors of the Digestive Tract.

Ber Y, Garcia-Lopez S, Gargallo-Puyuelo C, Gomollon F Nutrients. 2021; 13(7).

PMID: 34371835 PMC: 8308711. DOI: 10.3390/nu13072325.

Advances in nutritional therapy in inflammatory bowel diseases: Review.

Wedrychowicz A, Zajac A, Tomasik P World J Gastroenterol. 2016; 22(3):1045-66.

PMID: 26811646 PMC: 4716019. DOI: 10.3748/wjg.v22.i3.1045.

Nutritional aspect of pediatric inflammatory bowel disease: its clinical importance.

Kim S, Koh H Korean J Pediatr. 2015; 58(10):363-8.

PMID: 26576179 PMC: 4644763. DOI: 10.3345/kjp.2015.58.10.363.

Crohn's disease and growth deficiency in children and adolescents.

Gasparetto M, Guariso G World J Gastroenterol. 2014; 20(37):13219-33.

PMID: 25309059 PMC: 4188880. DOI: 10.3748/wjg.v20.i37.13219.

Can early onset of disease be one of the risk factors for low bone mineral density in patients with inflammatory bowel disease?.

Kwon K, Ku Y Clin Endosc. 2013; 46(1):5-6.

PMID: 23424712 PMC: 3572351. DOI: 10.5946/ce.2013.46.1.5.

References

Griffiths A, Nguyen P, Smith C, MacMillan J, Sherman P . Growth and clinical course of children with Crohn's disease. Gut. 1993; 34(7):939-43. PMC: 1374230. DOI: 10.1136/gut.34.7.939. View

Bernstein C, Leslie W . Review article: Osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 19(9):941-52. DOI: 10.1111/j.1365-2036.2004.01876.x. View

Bernstein C, Seeger L, Sayre J, Anton P, Artinian L, Shanahan F . Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995; 10(2):250-6. DOI: 10.1002/jbmr.5650100211. View

Jahnsen J, Falch J, Aadland E, Mowinckel P . Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997; 40(3):313-9. PMC: 1027079. DOI: 10.1136/gut.40.3.313. View

Schoon E, van Nunen A, Wouters R, Stockbrugger R, Russel M . Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl. 2001; (232):43-7. View

Henderson S, Hoffman N, Prince R . A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 101(1):119-23. DOI: 10.1111/j.1572-0241.2006.00372.x. View

Schulte C, Dignass A, Mann K, Goebell H . Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4(4):268-75. DOI: 10.1002/ibd.3780040403. View

Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray T, Blondeau L . Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2001; 11(10):897-904. DOI: 10.1007/s001980070050. View

Szathmari M, Pronai L, Tulassay Z . Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1998; 93(5):848-9. DOI: 10.1111/j.1572-0241.1998.848_a.x. View

10.

Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z . Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis. 2006; 24(1-2):201-6. DOI: 10.1159/000091299. View

11.

Walsh M, Kim N, Kadono Y, Rho J, Lee S, Lorenzo J . Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006; 24:33-63. DOI: 10.1146/annurev.immunol.24.021605.090646. View

12.

Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C . Reduced bone density in patients with inflammatory bowel disease. Gut. 1997; 40(2):228-33. PMC: 1027054. DOI: 10.1136/gut.40.2.228. View

13.

Driscoll Jr R, Meredith S, Sitrin M, Rosenberg I . Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology. 1982; 83(6):1252-8. View

14.

Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M . Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995; 108(2):417-22. DOI: 10.1016/0016-5085(95)90068-3. View

15.

Compston J, Judd D, Crawley E, Evans W, Evans C, Church H . Osteoporosis in patients with inflammatory bowel disease. Gut. 1987; 28(4):410-5. PMC: 1432817. DOI: 10.1136/gut.28.4.410. View

16.

Yang S, Yun S, Kim J, Park J, Kim H, Kim Y . Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2007; 14(4):542-9. DOI: 10.1002/ibd.20310. View

17.

Sonnenberg A, Ehms H, Sonnenberg G, Strohmeyer G . 25-hydroxycholecalciferol serum levels in patients with Crohn's disease. Acta Hepatogastroenterol (Stuttg). 1977; 24(4):293-5. View

18.

Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, du Puy Montbrun T . Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992; 37(9):1396-403. DOI: 10.1007/BF01296010. View

19.

Vestergaard P . Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol. 2003; 15(8):851-6. DOI: 10.1097/00042737-200308000-00003. View

20.

Cowan F, Warner J, Dunstan F, Evans W, Gregory J, Jenkins H . Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997; 76(4):325-9. PMC: 1717165. DOI: 10.1136/adc.76.4.325. View